In our study we were able to give up to four doses in some subjects ... Most side effects were limited to mild, temporary ...
The new approval allows patients to transition to a single 200mg subcutaneous injection once every 4 weeks, following completion of the induction phase.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results